MCID: KLB004
MIFTS: 27

Klebsiella Infection

Categories: Rare diseases

Aliases & Classifications for Klebsiella Infection

MalaCards integrated aliases for Klebsiella Infection:

Name: Klebsiella Infection 52
Klebsiella Infections 71
Klebsiella 52

Classifications:



External Ids:

UMLS 71 C0022729

Summaries for Klebsiella Infection

NIH Rare Diseases : 52 Klebsiella is a type of bacteria commonly found in nature. In humans, the bacteria are often present in parts of the digestive tract where they do not generally cause problems. In the United States, Klebsiella pneumoniae and Klebsiella oxytoca are the two strains responsible for most human illnesses. Many Klebsiella infections are acquired in the hospital setting or in long-term care facilities. In fact, Klebsiellae account for up to 8% of all hospital-acquired infections. People with a compromised immune system and/or people who have an implanted medical device (such as a urinary catheter or airway tube) are more at risk for Klebsiella infections. Extensive use of antibiotics has resulted in the development of antibiotic-resistant strains of Klebsiella . These infections can be more aggressive and difficult to treat.

MalaCards based summary : Klebsiella Infection, also known as klebsiella infections, is related to granuloma inguinale and rhinoscleroma. An important gene associated with Klebsiella Infection is LCN2 (Lipocalin 2). The drugs Norfloxacin and Cefuroxime have been mentioned in the context of this disorder. Affiliated tissues include colon, liver and kidney.

Related Diseases for Klebsiella Infection

Diseases related to Klebsiella Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 475)
# Related Disease Score Top Affiliating Genes
1 granuloma inguinale 11.7
2 rhinoscleroma 11.6
3 klebsiella pneumonia 11.6
4 immunodeficiency 30 11.2
5 suppressor of tumorigenicity 11 10.9
6 48,xyyy 10.9
7 endophthalmitis 10.8
8 pneumonia 10.8
9 meningitis 10.7
10 toxic shock syndrome 10.7
11 mastitis 10.5
12 osteomyelitis 10.5
13 endocarditis 10.5
14 neutropenia 10.4
15 fasciitis 10.4
16 necrotizing fasciitis 10.4
17 colitis 10.4
18 septic arthritis 10.4
19 uveitis 10.4
20 bacteriuria 10.3
21 cystitis 10.3
22 bacterial meningitis 10.3
23 enterocolitis 10.3
24 disseminated intravascular coagulation 10.3
25 rhinitis 10.3
26 liver cirrhosis 10.3
27 iridocyclitis 10.3
28 cellulitis 10.3
29 hypopyon 10.3
30 alcohol dependence 10.3
31 bacteremia 2 10.3
32 lung abscess 10.3
33 haemophilus influenzae 10.3
34 helix syndrome 10.2
35 respiratory failure 10.2
36 infective endocarditis 10.2
37 thrombophlebitis 10.2
38 atrophic rhinitis 10.2
39 arthritis 10.2
40 overgrowth syndrome 10.2
41 otitis media 10.2
42 bronchopneumonia 10.2
43 intestinal disease 10.2
44 epidural abscess 10.2
45 gastroenteritis 10.2
46 acute kidney failure 10.2
47 pyomyositis 10.2
48 biliary tract disease 10.2
49 spinal cord injury 10.2
50 splenic abscess 10.1

Graphical network of the top 20 diseases related to Klebsiella Infection:



Diseases related to Klebsiella Infection

Symptoms & Phenotypes for Klebsiella Infection

Drugs & Therapeutics for Klebsiella Infection

Drugs for Klebsiella Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norfloxacin Approved Phase 4 70458-96-7 4539
2
Cefuroxime Approved Phase 4 55268-75-2 5479529 5361202
3
Ampicillin Approved, Vet_approved Phase 4 69-53-4 6249
4
leucovorin Approved Phase 4 58-05-9 6006 143
5
Sulfamethoxazole Approved Phase 4 723-46-6 5329
6
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
7
Fosfomycin Approved Phase 4 23155-02-4 446987
8
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
9
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
10
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
11
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
12
Polyestradiol phosphate Approved Phase 4 28014-46-2
13
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
14
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
15
Zinc Approved, Investigational Phase 4 7440-66-6 32051
16
Zinc oxide Approved Phase 4 1314-13-2
17 Benzethonium Approved Phase 4 10172-60-8
18
Tazobactam Approved Phase 4 89786-04-9 123630
19
Piperacillin Approved Phase 4 66258-76-2 43672
20
Ceftriaxone Approved Phase 4 73384-59-5 5361919 5479530
21
Meropenem Approved, Investigational Phase 4 96036-03-2, 119478-56-7 441130 64778
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
23 cefuroxime axetil Phase 4
24 Cytochrome P-450 Enzyme Inhibitors Phase 4
25 Folic Acid Antagonists Phase 4
26 Vitamin B Complex Phase 4
27 Antiprotozoal Agents Phase 4
28 Antiparasitic Agents Phase 4
29 Folate Phase 4
30 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
31 Antimalarials Phase 4
32 Vitamin B9 Phase 4
33 Contraceptive Agents Phase 4
34 Estradiol 17 beta-cypionate Phase 4
35 Contraceptives, Oral, Combined Phase 4
36 Estradiol 3-benzoate Phase 4
37 Contraceptives, Oral Phase 4
38 Norgestimate, ethinyl estradiol drug combination Phase 4
39 Anti-Retroviral Agents Phase 4
40 Pharmaceutical Solutions Phase 4
41 Chlorhexidine gluconate Phase 4
42 Anti-Infective Agents, Local Phase 4
43 Benzalkonium Compounds Phase 4
44 Piperacillin, Tazobactam Drug Combination Phase 4
45 beta-Lactamase Inhibitors Phase 4
46
Edetic Acid Approved, Vet_approved Phase 3 60-00-4, 62-33-9 6049
47
Sulbactam Approved Phase 3 68373-14-8
48
Pentetic acid Approved Phase 3 67-43-6
49
Clarithromycin Approved Phase 3 81103-11-9 84029
50
Imipenem Approved Phase 3 74431-23-5, 64221-86-9 104838

Interventional clinical trials:

(show top 50) (show all 129)
# Name Status NCT ID Phase Drugs
1 SELECTIVE DIGESTIVE DECONTAMINATION USING ORAL GENTAMICIN AND ORAL POLYMYXIN E FOR ERADICATION OF CARBAPENEM-RESISTANT KLEBSIELLA PNEUMONIAE CARRIAGE IN HOSPITALIZED PATIENTS Unknown status NCT01761487 Phase 4
2 Use Of High Dose Colistin in Multi Drug Resistant Gram Negative Infections in Critically Ill Adult Patients. Randomized Controlled Clinical Trial Unknown status NCT02162966 Phase 4 High Dose Colistin;Standard Dose Colistin
3 Noroxin Efficacy and Safety Trial Unknown status NCT03506256 Phase 4 Norfloxacin 400 MG
4 Comparison of Two Antibiotic Prophylactic Protocols in Preterm Premature Rupture of the Membranes. A Randomized Prospective, Open Trial Unknown status NCT02819570 Phase 4 I.V cefuroxime 750 mg*3/d for 2 days;I.V ampicillin 2 gram x4/d for 2 days;P.O cefuroxime 500 mgx2/d for 5 days;P.O roxithromycin 150 mg*2/d for 7 days;P.O moxypen 500 mgx3/d for 5 days
5 A Multi-centre Randomised Open-label Active Comparator-controlled Non-inferiority Trial Comparing Oral to Intravenous Antibiotics in the Early Management of Klebsiella Pneumoniae Liver Abscess Completed NCT01723150 Phase 4 Ciprofloxacin;Ceftriaxone;Trimethoprim/sulfamethoxazole;Ertapenem
6 Comparison of Moxifloxacin With Ciprofloxacin/Metronidazole as Adjunctive Therapy to Mechanical Treatment of Patients With Chronic Periodontitis Completed NCT00805558 Phase 4 moxifloxacin;Ciprofloxacin plus metronidazole
7 Randomized Clinical Trial to Assess Whether the Duration of Cotrimoxazole Preventive Therapy in HIV Patients With CD4 Counts >350 CD4 Cells/µL by Antiretroviral Treatment Influences the Rate of Carriage of Multidrug-resistant Bacteria Completed NCT03087890 Phase 4 Cotrimoxazole;Placebo
8 Perioperative Disodium Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients. Controlled Clinical Trial (PERIFOS Trial) Completed NCT03235947 Phase 4 Fosfomycin disodium;Trimethoprim / Sulfamethoxazole;Intravenous placebo
9 Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic Urinary Tract Infections Due to Extended-spectrum β-lactamase (ESBL)-Producing Escherichia Coli or Klebsiella Pneumoniae - (CAPITIS Study) Recruiting NCT03891433 Phase 4 Meropenem;Ertapenem 1000 MG;Piperacillin, Tazobactam 4-0.5G Solution for Injection
10 Ceftaroline Pharmacokinetics in Critically Ill Patients Receiving Continuous Renal Replacement Therapy Recruiting NCT04152694 Phase 4
11 A Study of Efficacy of Chlorhexidine Scrub, ZnO Nanoparticles Socks and the Combination of Chlorhexidine Scrub and ZnO Nanoparticles Socks for Prevention of Pitted Keratolysis Not yet recruiting NCT04337749 Phase 4 Chorhexidine scrub
12 A Study of Efficacy of Chlorhexidine Scrub, ZnO Nanoparticles Socks and the Combination of Chlorhexidine Scrub and ZnO Nanoparticles Socks for Treatment of Pitted Keratolysis Not yet recruiting NCT04332796 Phase 4 Chorhexidine scrub
13 Randomized Controlled Trial of Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Due to Ceftriaxone Non-susceptible E. Coli and Klebsiella Species. Terminated NCT02176122 Phase 4 Meropenem;Piperacillin-tazobactam combination product
14 The Role of Synbiotics in Reducing Post-Operative Infections in Patients Undergoing Cardiac Surgery: A Pilot Study Terminated NCT00164099 Phase 4 Synbiotic 2000
15 Efficacy and Safety of Colistin for Therapy of Infections Caused by Extended Spectrum Beta-Lactamase(ESBL) Producing Klebsiella Pneumoniae or Escherichia Coli Unknown status NCT00300560 Phase 3 Colistin
16 A Phase 3, Open-label, Noncomparative Study of Tigecycline for the Treatment of Subjects With Selected Serious Infections Due to Resistant Gram-negative Organisms Such as Enterobacter Species, Acinetobacter Baumannii, and Klebsiella Pneumoniae Completed NCT00079989 Phase 3 tigecycline
17 The Effect Of Polivalent Mechanical Bacterial Lysate On The Clinical Course Of Grass Pollen-Induced Allergic Rhinitis In Children Completed NCT04270552 Phase 3 Ismigen;Placebo
18 Multicentre, Randomised, Double Blind, Placebo-controlled Study of the Efficacy and Safety of Broncho-Vaxom (OM 85 BV) in Children Suffering From Atopic Dermatitis Completed NCT03047954 Phase 3 Broncho-Vaxom;Placebo - Cap
19 A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT) Completed NCT01371656 Phase 3 levofloxacin
20 Randomized, Double-blind, Double-dummy, Active-controlled, Multi-centre Trial to Compare the Efficacy and Safety of CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) With Meropenem in Infections Caused by β-Lactamase (ESBL and MBL) Producing Gram-Negative Bacteria Completed NCT03477422 Phase 3 CSE-1034 (Ceftriaxone + Sulbactam + EDTA);Meropenem
21 A Double-blind Randomized Placebo-controlled Clinical Trial of the Safety and Efficacy of Intravenous Clarithromycin as Immunomodulatory Therapy for the Management of Sepsis Completed NCT01223690 Phase 3 Clarithromycin;Dextrose 5%
22 Diagnosis of Ventilator- Associated Pneumonia in Children: A Comparative Study of Bronchoscopic and Non-Bronchoscopic Methods Completed NCT00495963 Phase 3
23 Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients Recruiting NCT02729116 Phase 2, Phase 3 Sitafloxacin;Ertapenem
24 Polymyxin B Monotherapy Versus Polymyxin B-Carbapenem Combination Therapy in Critically Ill Patients With Multi-drug Resistant Gram-negative Infection: A Prospective, Parallel-Group, Double-Blind, Randomized Controlled Study Recruiting NCT03159078 Phase 3 Polymyxin B
25 Randomized Controlled Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli Recruiting NCT01597973 Phase 3 colistin and meropenem;colistin and placebo
26 Pre-delivery Administration of Azithromycin to Prevent Neonatal Sepsis and Death: a Phase III Double-blind Randomized Clinical Trial Recruiting NCT03199547 Phase 3 Azithromycin;Placebo Oral Tablet
27 Efficacy of Empirical Ciprofloxacin Plus Metronidazole and Cefixime Plus Metronidazole Therapy for the Treatment of Liver Abscess: A Randomised Controlled Clinical Trial Not yet recruiting NCT03969758 Phase 3 Ciprofloxacin;Cefixime
28 PCSK9 Inhibitor: a New Tool to Fight Septic Shock Not yet recruiting NCT03634293 Phase 2, Phase 3 Alirocumab Injectable Product;Saline Solution
29 Multi-center, Open-label Randomized Controlled Trial on the Efficacy of Combination Antibiotic Therapy for Serious Infections Caused by Extensively Drug-resistant Gram-negative Bacteria (XDR-GNB) Withdrawn NCT02134106 Phase 2, Phase 3 Polymyxin B;Polymyxin B + Doripenem
30 Safety and Efficacy Study of Eradication of Carbapenem Resistant Klebsiella Pneumonia From the Gastrointestinal Tract by Probiotics. Unknown status NCT00722410 Phase 1, Phase 2 Polyethylene glycol
31 Pilot Study of the Effectiveness of Probiotics and Lactitol for the Intestinal Decolonization of People Carriers of Klebsiella Pneumoniae Producers of Carbapenemase OXA-48-type: DesProbiOXA Study Unknown status NCT02307383 Phase 2 Lactitol;Lactobacillus
32 Investigator Driven Randomized Controlled Trial of Cefiderocol Versus Standard Therapy for Healthcare Associated and Hospital Acquired Gram-negative Blood Stream Infection: Study Protocol (the GAME CHANGER Trial) Recruiting NCT03869437 Phase 2 Cefiderocol
33 Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance The SCOUT Study: "Short Course Therapy for Urinary Tract Infections in Children" Active, not recruiting NCT01595529 Phase 2 Cefixime;Cephalexin;Trimethoprim/Sulfamethoxazole
34 Pentaglobin as Early Adjuvant Treatment for Febrile Neutropenia in Acute Leukemia or Allogeneic Hematopoietic Stem Cell Transplant Patients Colonized by Carbapenem-resistant Enterobacteriaceae (CRE) or Pseudomonas Aeruginosa (PA) Not yet recruiting NCT03494959 Phase 2 Pentaglobin
35 Treatment of Renal Stones With Frankincense (Boswellic Acid): A Clinical Randomized Trial Not yet recruiting NCT03924596 Phase 1, Phase 2 AKBA-Incense (3-acetyl-11-keto-ß-boswellic acid);Potassium Sodium Hydrogen Citrate
36 New Prognostic Classification of Acute Pyelonephritis With Adaptation of the Therapeutic. Prospective Randomized Study in the Emergency Terminated NCT01628900 Phase 2
37 A Randomized, Open-Label, Active Controlled Study to Evaluate the Safety and Tolerability of a Phage Cocktail-SPK Therapy in Second Degree Burn Wounds in Adult Patients Not yet recruiting NCT04323475 Phase 1 Xeroform
38 A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple-Dose Study of the Safety, Tolerability and Pharmacokinetics of Intravenous (IV) QPX7728 Alone and in Combination With QPX2014 in Healthy Adult Subjects Not yet recruiting NCT04380207 Phase 1 QPX7728;Placebo;QPX2014
39 A Placebo-Controlled, Blinded, Dose-Escalation, Study to Assess the Safety and Pharmacodynamics of Single and Multiple Doses of QBKPN (Inactivated Klebsiella Pneumoniae) Site Specific Immunomodulator (SSI), Administered Subcutaneously to Healthy Male and Female Volunteers Withdrawn NCT02897999 Phase 1
40 Epidemiological Characteristics and Treatment Protocol for Carbapenem-Resistant Klebsiella Pneumoniae in China Unknown status NCT03245632
41 Feasibility Studies to Inform Novel Proposals to Avert Community-Based Antimicrobial Resistance Spread Unknown status NCT02666274
42 Gemifloxacin Versus Ciprofloxacin Versus Rifampicin in Treatment of Rhinoscleroma Unknown status NCT03326050 Early Phase 1 Gemifloxacin;Ciprofloxacin;Rifampicin
43 Oral and Tracheal Cultures in Pediatric ICU Patients Compared to Healthy Children Unknown status NCT03418272
44 Experimental Phage Therapy of Drug-resistant Bacterial Infections, Including MRSA Infections Unknown status NCT00945087
45 Epidemiology of Extended-spectrum ß-lactamase (ESBL)-Producing Enteric Gram-negative Bacilli in Swiss Children Unknown status NCT00894036
46 Impact of Specific Antibiotic Therapies on the Prevalence of Human Host Resistant Bacteria in Hospitalised Patients (SATURN 04) Unknown status NCT01208519
47 Microbiology and Clinical Outcome of Community Acquired Pneumonia and Health-Care-Associated Pneumonia in Taiwan: a Multi-Center Study Unknown status NCT00873522
48 Bacterial Contamination of Critical Care Observation Charts: a Randomized Trial Comparing Matt and Antimicrobial Cellomed Laminates. Unknown status NCT01245829
49 Bacteremia in Intensive Care Unit (ICU) and the Role of Toll-Like-Receptors (TLRs) Unknown status NCT00932243
50 Extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL) Vertical Transmission in Preterm Labor Unknown status NCT03251885

Search NIH Clinical Center for Klebsiella Infection

Inferred drug relations via UMLS 71 / NDF-RT 50 :


cefditoren
CEFTIBUTEN DIHYDRATE
Ciprofloxacin
Enoxacin
lomefloxacin

Genetic Tests for Klebsiella Infection

Anatomical Context for Klebsiella Infection

MalaCards organs/tissues related to Klebsiella Infection:

40
Colon, Liver, Kidney, Testes, Whole Blood, Lung, Neutrophil

Publications for Klebsiella Infection

Articles related to Klebsiella Infection:

(show top 50) (show all 195)
# Title Authors PMID Year
1
Development and evaluation of a new recombinant protein vaccine (YidR) against Klebsiella pneumoniae infection. 61
32444194 2020
2
Caspase-11 contributes to pulmonary host defense against Klebsiella pneumoniae and local activation of coagulation. 61
32401674 2020
3
Efflux pump activity, biofilm formation and antibiotic resistance profile of Klebsiella spp. isolated from clinical samples at Lagos University Teaching Hospital. 61
32456668 2020
4
Detection of multiple hypervirulent Klebsiella pneumoniae strains in a New York City hospital through screening of virulence genes. 61
32461145 2020
5
Clinics in Diagnostic Imaging: COVID-19 atypical pneumonia. 61
32241067 2020
6
Elevated urinary IL-1β levels in multidrug resistant Escherichia coli and Klebsiella infections. 61
31820023 2020
7
Could platelet to leucocytic count ratio (PLR) predict sepsis and clinical outcomes in patients with emphysematous pyelonephritis? 61
31103341 2019
8
Diversity of clonal types of Klebsiella pneumoniae causing infections in intensive care neonatal patients in a large urban setting. 61
31401781 2019
9
Mucoviscous characteristics of Klebsiella pneumoniae strains: A factor of clinical severity? 61
31257062 2019
10
Klebsiella pneumoniae infection biology: living to counteract host defences. 61
30452654 2019
11
Sphenoid Sinus Cholesteatoma-Complications and Skull Base Osteomyelitis: Case Report and Review of Literature. 61
30858746 2019
12
Colistin-Resistant Klebsiella Infections Among Pediatric Oncology and Hematopoietic Stem Cell Transplantation Patients in Eastern India. 61
29173228 2018
13
Incidence of Extended-Spectrum β-Lactamase (ESBL)-Producing Escherichia coli and Klebsiella Infections in the United States: A Systematic Literature Review. 61
28758612 2017
14
Combination Therapy for Multidrug-Resistant Klebsiella Pneumoniae Urinary Tract Infection. 61
28948123 2017
15
Alcohol-associated intestinal dysbiosis impairs pulmonary host defense against Klebsiella pneumoniae. 61
28604843 2017
16
Mincle-Mediated Neutrophil Extracellular Trap Formation by Regulation of Autophagy. 61
28186242 2017
17
Newborn with rash due to Klebsiella infection. 61
28012933 2017
18
Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study. 61
27729016 2016
19
Ozena in Immigrants of Differing Backgrounds. 61
27114295 2016
20
BamB and outer membrane biogenesis - The Achilles' heel for targeting Klebsiella infections? 61
27129024 2016
21
Uncommon cause of acute encephalopathy in liver cirrhosis. 61
27194673 2016
22
A Comparative Study on Antibiotic Resistance of Klebsiella Strains from Surgical and Intensive Care Wards. 61
30568829 2016
23
Epidemiology and Virulence of Klebsiella pneumoniae. 61
26999397 2016
24
Deciphering tissue-induced Klebsiella pneumoniae lipid A structure. 61
26578797 2015
25
Vaccination with Klebsiella pneumoniae-derived extracellular vesicles protects against bacteria-induced lethality via both humoral and cellular immunity. 61
26358222 2015
26
Multi-drug carbapenem-resistant Klebsiella pneumoniae infection carrying the OXA-48 gene and showing variations in outer membrane protein 36 causing an outbreak in a tertiary care hospital in Riyadh, Saudi Arabia. 61
25245001 2014
27
Prevalence of two multidrug-resistant Klebsiella species in an Indian teaching hospital and adjoining community. 61
24996691 2014
28
Antibiotic-loaded cement spacer for treatment of Klebsiella infected total hip and knee arthroplasty. 61
25518276 2014
29
Hypermucoviscous Klebsiella syndrome without liver abscess in a patient with immunoglobulin g2 immune deficiency. 61
25734148 2014
30
Klebsiella pneumoniae Infection: A Virulent Cause of Visual Loss. 61
25606041 2014
31
[Frequency of occurrence of ivyC and pliC lysozyme inhibitors genes in clinical klebsiella strains]. 61
25286520 2014
32
Microbiological and Genetic Characterization of Carbapenem-Resistant Klebsiella pneumoniae Isolated From Pediatric Patients. 61
24567846 2014
33
[Effects of PM2.5 exposure on Klebsiella pneumoniae clearance in the lungs of rats]. 61
24507396 2013
34
The emergence of Klebsiella pneumoniae endogenous endophthalmitis in the USA: basic and clinical advances. 61
23514342 2013
35
Detection of magA Gene in Klebsiella spp. Isolated from Clinical SamplesDetection of magA. 61
24298386 2013
36
Antimicrobial sensitivity patterns of cerebrospinal fluid (CSF) isolates in Namibia: implications for empirical antibiotic treatment of meningitis. 61
24764539 2013
37
Bacterial isolates and its antibiotic susceptibility pattern in NICU. 61
23774417 2013
38
Evaluation of virulent multidrug resistant Klebsiella infection status in a tertiary care hospital in Eastern India. 61
23785917 2012
39
Incidence, aetiology and resistance of late-onset neonatal sepsis: a five-year prospective study. 61
22404730 2012
40
Development of a new trend conjugate vaccine for the prevention of Klebsiella pneumoniae. 61
24470947 2012
41
Intrapulmonary administration of leukotriene B(4) augments neutrophil accumulation and responses in the lung to Klebsiella infection in CXCL1 knockout mice. 61
22379035 2012
42
CXCL1 regulates pulmonary host defense to Klebsiella Infection via CXCL2, CXCL5, NF-kappaB, and MAPKs. 61
20937845 2010
43
Clinical disease caused by Klebsiella in 2 unrelated patients with interleukin 12 receptor beta1 deficiency. 61
20855390 2010
44
Both TRIF- and MyD88-dependent signaling contribute to host defense against pulmonary Klebsiella infection. 61
19846873 2009
45
Fatal cross infection by carbapenem-resistant Klebsiella in two liver transplant recipients. 61
19254325 2009
46
Lipocalin 2 is required for pulmonary host defense against Klebsiella infection. 61
19342674 2009
47
[Choice of probiotic for rational therapy of infection caused by Klebsiella in children]. 61
19462517 2009
48
Causative agents and antimicrobial susceptibilities of urinary tract infections in the northwest of Iran. 61
18703368 2009
49
Effects of chelators (deferoxamine, deferiprone and deferasirox) on the growth of Klebsiella pneumoniae and Aeromonas hydrophila isolated from transfusion-dependent thalassemia patients. 61
19814682 2009
50
Outcome of gram negative infection in immunocompromised children. 61
18493995 2008

Variations for Klebsiella Infection

Expression for Klebsiella Infection

Search GEO for disease gene expression data for Klebsiella Infection.

Pathways for Klebsiella Infection

GO Terms for Klebsiella Infection

Sources for Klebsiella Infection

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....